Product Name:Ziconotide Acetate,Prialt
CAS Subcriptio Number: 107452-89-1
Formulae hypotheticae: C102H172N36O32S7
M. Pondus: 2639.01
Sequentia: Cys-Lys-Gly-Lys-Gly Ala-Lys-Cys Ser-Arg-Leu-Met-Tyr Asp-Cys-Thr-Gly Ser-Cys Arg-Ser Gly-Ly-Cys NH2(Disfulde pontem: 1-16, 8-20, 15-25)
Aspectus: Alba pulveris
Gradus: Pharmaceutical Grade
Aqua Content(Carolus Fischer): 5.0%
Acetate Content(per HPLC *): 12.0%
Amino Acidum Compositio: 10% theoretical
Puritas(per HPLC *): 98.0%
una immunditia(per HPLC *): 1.0%
Peptide Content(by %N ): 80%
Assay(per Anhydrous, Acidum aceticum-liberum ): 95.0~105.0%
Repono: Cool(2~8 ) & siti tuta lux, sarcina proxima, cum in usu non custodiant.
Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail Conus magus comprising 25 amino acids with three disulphide bonds. Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be synthesized without loss of proper bond formation or structural elements.Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.
Ziconotide is an N-type calcium channel antagonist used to manage patients with severe chronic pain who cannot tolerate, or who have not responded adequately to other treatments such as intrathecal morphine and systemic analgesics.
Ziconotide inhibits N-type calcium channels involved in nociceptive signalling, primarily in the dorsal horn of the spinal cord.Although binding is reversible, careful dosing is required to ensure therapeutic effects while minimizing adverse effects, and ziconotide has been described as possessing a narrow therapeutic window.Patients taking ziconontide may experience cognitive and neuropsychiatric symptoms, reduced levels of consciousness, and elevated serum creatine kinase levels. Autem, ziconotide may increase the risk of infection, including serious cases of meningitis. Patients who withdraw from opiates for ziconotide initiation are advised to taper off the dose.
